208 related articles for article (PubMed ID: 20940050)
1. Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo.
Nordly P; Korsholm KS; Pedersen EA; Khilji TS; Franzyk H; Jorgensen L; Nielsen HM; Agger EM; Foged C
Eur J Pharm Biopharm; 2011 Jan; 77(1):89-98. PubMed ID: 20940050
[TBL] [Abstract][Full Text] [Related]
2. Nano-Self-Assemblies Based on Synthetic Analogues of Mycobacterial Monomycoloyl Glycerol and DDA: Supramolecular Structure and Adjuvant Efficacy.
Martin-Bertelsen B; Korsholm KS; Roces CB; Nielsen MH; Christensen D; Franzyk H; Yaghmur A; Foged C
Mol Pharm; 2016 Aug; 13(8):2771-81. PubMed ID: 27377146
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.
Davidsen J; Rosenkrands I; Christensen D; Vangala A; Kirby D; Perrie Y; Agger EM; Andersen P
Biochim Biophys Acta; 2005 Dec; 1718(1-2):22-31. PubMed ID: 16321607
[TBL] [Abstract][Full Text] [Related]
4. Influence of trehalose 6,6'-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes.
Kallerup RS; Madsen CM; Schiøth ML; Franzyk H; Rose F; Christensen D; Korsholm KS; Foged C
Eur J Pharm Biopharm; 2015 Feb; 90():80-9. PubMed ID: 25445301
[TBL] [Abstract][Full Text] [Related]
5. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice.
Vangala A; Kirby D; Rosenkrands I; Agger EM; Andersen P; Perrie Y
J Pharm Pharmacol; 2006 Jun; 58(6):787-99. PubMed ID: 16734980
[TBL] [Abstract][Full Text] [Related]
7. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
[TBL] [Abstract][Full Text] [Related]
8. A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4⁺ T-cell response.
Karlsen K; Korsholm KS; Mortensen R; Ghiasi SM; Andersen P; Foged C; Christensen D
Nanomedicine (Lond); 2014 Dec; 9(17):2625-38. PubMed ID: 25529567
[TBL] [Abstract][Full Text] [Related]
9. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen.
Henriksen-Lacey M; Bramwell VW; Christensen D; Agger EM; Andersen P; Perrie Y
J Control Release; 2010 Mar; 142(2):180-6. PubMed ID: 19874860
[TBL] [Abstract][Full Text] [Related]
10. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses.
Henriksen-Lacey M; Christensen D; Bramwell VW; Lindenstrøm T; Agger EM; Andersen P; Perrie Y
Mol Pharm; 2011 Feb; 8(1):153-61. PubMed ID: 21117621
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
13. Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach.
Rose F; Wern JE; Ingvarsson PT; van de Weert M; Andersen P; Follmann F; Foged C
J Control Release; 2015 Jul; 210():48-57. PubMed ID: 25957906
[TBL] [Abstract][Full Text] [Related]
14. Adjuvants Based on Synthetic Mycobacterial Cord Factor Analogues: Biophysical Properties of Neat Glycolipids and Nanoself-Assemblies with DDA.
Kallerup RS; Franzyk H; Schiøth ML; Justesen S; Martin-Bertelsen B; Rose F; Madsen CM; Christensen D; Korsholm KS; Yaghmur A; Foged C
Mol Pharm; 2017 Jul; 14(7):2294-2306. PubMed ID: 28497975
[TBL] [Abstract][Full Text] [Related]
15. Immune responses induced by nano-self-assembled lipid adjuvants based on a monomycoloyl glycerol analogue after vaccination with the Chlamydia trachomatis major outer membrane protein.
Rodrigues L; Raftopoulos KN; Tandrup Schmidt S; Schneider F; Dietz H; Rades T; Franzyk H; Pedersen AE; Papadakis CM; Christensen D; Winter G; Foged C; Hubert M
J Control Release; 2018 Sep; 285():12-22. PubMed ID: 29964134
[TBL] [Abstract][Full Text] [Related]
16. Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system.
McNeil SE; Rosenkrands I; Agger EM; Andersen P; Perrie Y
J Pharm Sci; 2011 May; 100(5):1856-65. PubMed ID: 21374619
[TBL] [Abstract][Full Text] [Related]
17. Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4
Schmidt ST; Neustrup MA; Harloff-Helleberg S; Korsholm KS; Rades T; Andersen P; Christensen D; Foged C
Pharm Res; 2017 Aug; 34(8):1716-1727. PubMed ID: 28516400
[TBL] [Abstract][Full Text] [Related]
18. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog.
Christensen D; Henriksen-Lacey M; Kamath AT; Lindenstrøm T; Korsholm KS; Christensen JP; Rochat AF; Lambert PH; Andersen P; Siegrist CA; Perrie Y; Agger EM
J Control Release; 2012 Jun; 160(3):468-76. PubMed ID: 22709414
[TBL] [Abstract][Full Text] [Related]
19. Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses.
Kaur R; Henriksen-Lacey M; Wilkhu J; Devitt A; Christensen D; Perrie Y
Mol Pharm; 2014 Jan; 11(1):197-207. PubMed ID: 24171445
[TBL] [Abstract][Full Text] [Related]
20. Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, fluidity and antigen-to-lipid ratio.
Hamborg M; Rose F; Jorgensen L; Bjorklund K; Pedersen HB; Christensen D; Foged C
Biochim Biophys Acta; 2014 Aug; 1838(8):2001-10. PubMed ID: 24769435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
